



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

January 14, 2012

**GE HEALTHCARE AND CARDIOCOMM SOLUTIONS, INC. ENTER A PRIVATE LABEL
MANUFACTURER AGREEMENT.**

GE Healthcare MARS Cardiac Event Station and MARS Event Station Lite to be the Private Label for Canadian GEMS Sales Through GE Healthcare.

Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of ECG acquisition and management software solutions is pleased to announce a private labelling agreement with GE Healthcare’s Diagnostic Cardiology business. The agreement clears the regulatory path for CardioComm Solutions to private label their Global ECG Management System (“GEMS”) for GE Healthcare under the GE Healthcare MARS Cardiac Event Station and MARS Event Station Lite for sale in Canada.

The agreement is complementary to an existing OEM agreement between the two companies and will permit GE Healthcare’s MARS Event Station and MARS Event Station Lite software, provided by CardioComm Solutions, to be filed with the Therapeutic Products Directorate of Canada. The authorization will also permit GE Healthcare and Health Canada to cross-reference the Company’s original GEMS medical device licence (“MDL”) materials, licensed by Health Canada under Licence No. 36225, in support of the GE Healthcare MDL application. This authorization is valid until June 30th 2014.

Yuval Shaked, General Manager of GE Healthcare’s Diagnostic Cardiology business, added “CardioComm Solutions and GE Healthcare have had a long relationship ensuring that our customers continue to have access to the latest ambulatory ECG event management solutions available. CardioComm Solutions continues to be a preferred supplier of these solutions and we look forward to continuing our collaboration with them.”

“Our continuing partnership with Healthcare confirms the medical validation of our ECG management solutions within the highly competitive hospital market. GE Healthcare is a recognized global leader in providing physicians and patients access to important and life saving diagnostic technologies and the MARS Cardiac Event Station solution is such an example” stated Etienne Grima, Chief Executive Officer for CardioComm Solutions. “We have had a very busy 2102 with the release of several new and disruptive ECG management and arrhythmia detection technologies. These advances leverage a platform of stable and medically credentialed software solutions, such as GEMS which forms our core ECG management solution for in-hospital installations. We thank GE Healthcare for their continued confidence and we look forward to the next two years in supporting GE Healthcare as a leader in the introduction of advanced cardiac monitoring and diagnostic technologies”.

About CardioComm Solutions

CardioComm Solution’s patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION ON CARDIOCOMM SOLUTIONS PLEASE CONTACT:
Etienne Grima, Chief Executive Officer



1-877-977-9425

egrima@cardiocommsolutions.com

www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release